Ultragenyx Pharma (RARE) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Ultragenyx Pharma (RARE) Has Multiple Catalysts in 2015 - Jefferies
March 26, 2015 8:36 AM EDTJefferies analyst Ryan Martins reiterated a Buy rating and $74 price target on Ultragenyx Pharma (NASDAQ: RARE) noting multiple catalysts in 2015.
Martins commented, "All of RARE's clinical programs are on track, with either phase 2 data or initiation of pivotal trials planned in 2015. Key updates included... More
Jefferies Weighs In on Ultragenyx Pharma (RARE) Related to SIMD Abstracts
March 25, 2015 7:34 AM EDTJefferies analyst Ryan Martins provided his take on SIMD abstracts relevant to Ultragenyx Pharma (NASDAQ: RARE). The firm reiterated a Buy rating and $74 price target.
Martins commented, "RARE will present 12 month data from the eIND patient on rhGUS, where we expect... More
